Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response
Journal of Investigative Dermatology · 2025
DOI: 10.1016/j.jid.2024.12.005 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Rashmi Tandon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Transcriptome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Innovative Medicines Initiative, European Federation of Pharmaceutical Industries and Associations.
Abstract (Originalsprache)
Atopic dermatitis is characterized by a complex epidermal barrier deficiency and exaggerated immune responses dominated by type 2 mechanisms with variable contributions of additional immune axes. IL-13 is overexpressed in atopic dermatitis skin and a key driver of both barrier dysfunction and inflammation. In this study, we prospectively studied the effects of IL-13 inhibition with tralokinumab on cutaneous transcriptome profiles using RNA sequencing of biopsies from 16 patients with moderate-to-severe atopic dermatitis obtained at baseline, week 2, and week 16. Tralokinumab therapy induced early and delayed expression changes and progressively shifted the transcriptomic profile of lesional toward nonlesional skin by modulating both genes associated with keratinocyte proliferation and differentiation, itch signaling, and downstream inflammatory responses. At week 16, 751 genes were still significantly dysregulated compared with those in healthy control skin, reinforcing the need for long-term immunomodulatory therapy of moderate-to-severe atopic dermatitis to achieve deep responses. The study was registered with ClinicalTrials.gov (NCT04556461).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. Electronic address: sweidinger@dermatology.uni-kiel.de.
Förderung
- Sanofi
- Innovative Medicines Initiative
- European Federation of Pharmaceutical Industries and Associations
- Horizon 2020 Framework Programme
- LEO Pharma
Zitieren
APA
Tandon, R., Harder, I., Stölzl, D., Hübenthal, M., Sander, N., Hartmann, J., Suhrkamp, I., Fonfara, M., Gerdes, S., & Weidinger, S. (2025). Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.12.005
Vancouver
Tandon R, Harder I, Stölzl D, Hübenthal M, Sander N, Hartmann J, et al. Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2024.12.005
BibTeX
@article{Tandon2025,
author = {Tandon, Rashmi and Harder, Inken and Stölzl, Dora and Hübenthal, Matthias and Sander, Nicole and Hartmann, Jan and Suhrkamp, Ina and Fonfara, Melina and Gerdes, Sascha and Weidinger, Stephan},
title = {Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response},
journal = {Journal of Investigative Dermatology},
year = {2025},
doi = {10.1016/j.jid.2024.12.005}
}
EUVIMED